Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tg Therapeutics (TGTX) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to 18.16%.

  • Tg Therapeutics' EBITDA Margin rose 33400.0% to 18.16% in Q3 2025 from the same period last year, while for Sep 2025 it was 19.32%, marking a year-over-year increase of 195100.0%. This contributed to the annual value of 12.74% for FY2024, which is 39100.0% up from last year.
  • As of Q3 2025, Tg Therapeutics' EBITDA Margin stood at 18.16%, which was up 33400.0% from 24.69% recorded in Q2 2025.
  • In the past 5 years, Tg Therapeutics' EBITDA Margin ranged from a high of 69.22% in Q3 2023 and a low of 96923.75% during Q4 2022
  • Moreover, its 5-year median value for EBITDA Margin was 277.93% (2023), whereas its average is 8898.68%.
  • In the last 5 years, Tg Therapeutics' EBITDA Margin soared by 2000000000bps in 2021 and then plummeted by -929191400bps in 2022.
  • Over the past 5 years, Tg Therapeutics' EBITDA Margin (Quarter) stood at 4004.61% in 2021, then tumbled by -2320bps to 96923.75% in 2022, then surged by 100bps to 28.39% in 2023, then skyrocketed by 197bps to 27.68% in 2024, then tumbled by -34bps to 18.16% in 2025.
  • Its EBITDA Margin was 18.16% in Q3 2025, compared to 24.69% in Q2 2025 and 7.13% in Q1 2025.